Westwood Cardiology regular participates in national and
international clinical trials to help ensure that our patients have access to
the most current therapies available.
ON TARGET/TRANSCEND is a large
multi-center international study evaluating whether the combination of an ACE
(angiotensin converting enzyme) inhibitor and ARB (angiotensin receptor blocker) is more effective than an
ACE or ARB alone in reducing the risk of heart attack, stroke, heart failure
or death in patients with heart disease or peripheral vascular disease.
is a large multi-center NIH study evaluating whether exercise can reduce
mortality and hospitalization in patients with congestive heart failure.
is the largest heart failure quality improvement outpatient registry ever
undertaken, that is designed to assess and improve heart failure treatment
is an NIH infrastructure project that we are participating with in
coordination with Columbia University that is evaluating networks for optimal
CLOSURE I is an
FDA-approved study to determine if non-surgical patch closure of a congenital
heart defect (a patent foramen ovale or hole in the
atrial wall) can prevent future stroke in victims
of unexplained stroke at a young age.
established optimal treatment regiments for patients with atrial
evaluated the role of inflammation in patients with coronary artery disease
the first study to demonstrate the utility of angiotensin
receptor blockers in elderly patients with congestive heart failure
RELY is an international
multicenter trial evaluating the effectiveness of a novel blood thinner, dabigatran (an oral direct thrombin inhibitor) vs. coumadin in patients with atrial
fibrillation. This completed study led to the release of the new
anticoagulant Pradaxa (dabigatran)
helped establish the utility of defibrillators in patients with ischemic and nonischemic cardiomyopathies